Abbott Laboratories Director Makes Significant Stock Sale!
Abbott Gains After Upcoming Baby Formula Case Thrown Out
Investors in Abbott Laboratories (NYSE:ABT) Have Seen Notable Returns of 52% Over the Past Five Years
Abbott Laboratories Announces Executive Vice President's Retirement
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession
Abbott Laboratories | 10-Q: Q1 2025 Earnings Report
Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy
CIBC Introducing Additional U.S. Canadian Depositary Receipts
Abbott Integrates Libre's Data With Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
A Look Into Abbott Laboratories Inc's Price Over Earnings
Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials
Fund Update: KEYBANK NATIONAL ASSOCIATION/OH Just Disclosed New Holdings
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $145
Abbott Laboratories: Strategic Advancements and Market Positioning With Volt PFA Platform Drive Buy Rating
Abbott Highlights New AVEIR Data, Initiates Trial for the Company's Conduction System Pacing Technology
Express News | Abbott Laboratories - 83.5% Paf and 58.1% Persaf Patients Arrhythmia-Free After 12 Months
Express News | New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ Pfa System for Patients With Afib